Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder. The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” encompasses both composition and method claims for the company’s proprietary approach to preventing or delaying stress-induced behavioral responses. This notice indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. A corresponding patent was issued by the Japan Patent Office earlier this year.
The U.S. patent protection is a critical component of Silo’s strategy as it advances SPC-15 development for PTSD, adding to its biopharmaceutical intellectual property portfolio of issued and allowed patents. This development matters because it provides legal exclusivity for a potential treatment in an area with significant unmet need. PTSD affects millions worldwide, and current therapies often have limitations. By securing patent rights, Silo Pharma can protect its investment in research and development, potentially attracting partners or investors to further clinical trials. The notice of allowance is not a final grant but signals that the patent will be issued soon, barring any unforeseen issues.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. For more details, visit https://ibn.fm/Hh4Z6.
The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of over 75 brands within the Dynamic Brand Portfolio @ IBN. It provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to more than 5,000 outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
